Maryland State Retirement & Pension System purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,011 shares of the company’s stock, valued at approximately $659,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BBIO. Silvant Capital Management LLC bought a new stake in BridgeBio Pharma in the second quarter worth $28,000. Root Financial Partners LLC bought a new position in shares of BridgeBio Pharma during the third quarter valued at $28,000. SBI Securities Co. Ltd. increased its holdings in shares of BridgeBio Pharma by 55.3% during the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock valued at $29,000 after acquiring an additional 157 shares in the last quarter. Allworth Financial LP bought a new position in shares of BridgeBio Pharma during the second quarter valued at $31,000. Finally, Heritage Family Offices LLP purchased a new position in shares of BridgeBio Pharma in the 3rd quarter worth about $39,000. Institutional investors own 99.85% of the company’s stock.
Analyst Upgrades and Downgrades
BBIO has been the topic of a number of analyst reports. Weiss Ratings cut shares of BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. Barclays decreased their target price on shares of BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. UBS Group reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Friday, October 30th. Piper Sandler increased their price target on shares of BridgeBio Pharma from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Finally, Bank of America raised their price target on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Nineteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.42.
Check Out Our Latest Stock Analysis on BridgeBio Pharma
Insider Activity at BridgeBio Pharma
In related news, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the sale, the chief executive officer owned 495,686 shares in the company, valued at approximately $34,241,988.88. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the sale, the chief accounting officer directly owned 120,687 shares of the company’s stock, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.23% of the stock is owned by insiders.
BridgeBio Pharma Price Performance
Shares of NASDAQ:BBIO opened at $78.14 on Friday. The business has a 50-day simple moving average of $70.22 and a two-hundred day simple moving average of $72.78. BridgeBio Pharma, Inc. has a fifty-two week low of $62.50 and a fifty-two week high of $93.42.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million for the quarter, compared to analysts’ expectations of $293.47 million. During the same period in the previous year, the business earned ($0.95) EPS. The business’s revenue was up 192.6% compared to the same quarter last year. Research analysts expect that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.
BridgeBio Pharma Company Profile
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
Read More
- Five stocks we like better than BridgeBio Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
